$VERV
Verve Therapeutics, Inc. Stock $verv

$verv Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022003499 Filed on March 14, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.435M	$6.601M	$18.87M
YoY Change	173.75%	226.14%	258.92%
% of Gross Profit
Research & Development	$24.49M	$25.94M	$68.20M
YoY Change	115.87%	66.49%	92.82%
% of Gross Profit
Depreciation & Amortization	$500.0K	$472.0K	$1.500M
YoY Change	66.67%	86.56%	15.38%
% of Gross Profit
Operating Expenses	$31.93M	$32.54M	$87.07M
YoY Change	127.05%	84.89%	114.31%
Operating Profit	-$31.93M		-$87.07M
YoY Change	127.05%		114.31%
Interest Expense	$82.00K	$64.00K	$142.0K
YoY Change	310.0%	-3300.0%	-12.35%
% of Operating Profit
Other Income/Expense, Net	$1.759M	$1.139M	-$33.25M
YoY Change	120.43%	-119.21%	554.86%
Pretax Income	-$30.17M	-$31.34M	$120.3M
YoY Change	127.44%	33.17%	163.24%
Income Tax			$0.00
% Of Pretax Income			0.0%
Net Earnings	-$30.17M	-$31.34M	-$120.3M
YoY Change	127.44%	33.17%	163.24%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.62		-$4.48
Diluted Earnings Per Share	-$621.1K	-$647.6K	-$4.477M
COMMON SHARES
Basic Shares Outstanding	48.58M	48.17M	26.87M
Diluted Shares Outstanding	48.57M		26.87M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$323.3M	$360.4M	$360.4M
YoY Change	116.22%		399.84%
Cash & Equivalents	$91.42M	$64.33M	$64.33M
Short-Term Investments	$231.9M	$296.1M	$296.1M
Other Short-Term Assets	$5.531M	$6.686M	$6.686M
YoY Change	138.61%		260.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$328.8M	$367.1M	$367.1M
YoY Change	116.56%	396.35%	396.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.13M	$7.224M	$9.063M
YoY Change	113.99%	81.33%	127.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.702M	$2.696M	$7.933M
YoY Change	139.96%		1613.39%
Total Long-Term Assets	$20.41M	$17.00M	$17.00M
YoY Change	222.55%	282.19%	282.19%
TOTAL ASSETS
Total Short-Term Assets	$328.8M	$367.1M	$367.1M
Total Long-Term Assets	$20.41M	$17.00M	$17.00M
Total Assets	$349.2M	$384.1M	$384.1M
YoY Change	120.8%	389.87%	389.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.438M	$7.077M	$7.077M
YoY Change	-1.97%	19558.33%	19558.33%
Accrued Expenses	$10.93M	$12.99M	$14.95M
YoY Change	169.22%	80.72%	107.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.80M	$22.02M	$22.02M
YoY Change	121.47%	201.08%	201.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.048M	$377.0K	$4.748M
YoY Change	-66.12%		-51.78%
Total Long-Term Liabilities	$3.048M	$377.0K	$4.748M
YoY Change	-66.12%		-51.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.80M	$22.02M	$22.02M
Total Long-Term Liabilities	$3.048M	$377.0K	$4.748M
Total Liabilities	$17.85M	$26.77M	$26.77M
YoY Change	13.84%	56.0%	56.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$217.0M	-$186.9M
YoY Change		180.83%
Common Stock	$549.1M	$544.4M
YoY Change		20687.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$331.4M	$357.4M	$357.4M
YoY Change
Total Liabilities & Shareholders Equity	$349.2M	$384.1M	$384.1M
YoY Change	120.8%	389.87%	389.87%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$30.17M	-$31.34M	-$120.3M
YoY Change	127.44%	33.17%	163.24%
Depreciation, Depletion And Amortization	$500.0K	$472.0K	$1.500M
YoY Change	66.67%	86.56%	15.38%
Cash From Operating Activities	-$33.51M	-$28.04M	-$77.88M
YoY Change	121.3%	87.27%	120.84%
INVESTING ACTIVITIES
Capital Expenditures	$2.908M	-$981.0K	$4.359M
YoY Change	171.78%	2.94%	27.31%
Acquisitions
YoY Change
Other Investing Activities	$63.00M	-$56.00M	-$234.7M
YoY Change	392.8%	-536.17%	392.08%
Cash From Investing Activities	$60.09M	-$56.99M	-$239.1M
YoY Change	412.99%	-579.39%	367.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	505.0K	1.224M	377.1M
YoY Change	-99.46%	15200.0%	307.1%
NET CHANGE
Cash From Operating Activities	-33.51M	-28.04M	-77.88M
Cash From Investing Activities	60.09M	-56.99M	-239.1M
Cash From Financing Activities	505.0K	1.224M	377.1M
Net Change In Cash	27.09M	-83.80M	60.11M
YoY Change	-70.03%	2620.91%	864.09%
FREE CASH FLOW
Cash From Operating Activities	-$33.51M	-$28.04M	-$77.88M
Capital Expenditures	$2.908M	-$981.0K	$4.359M
Free Cash Flow	-$36.42M	-$27.06M	-$82.24M
YoY Change	124.63%	93.0%	112.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	100
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	verv	Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2019	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised
CY2020	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2019	verv	Settlement Of Tranche Right Lliability SettlementOfTrancheRightLliability
CY2019	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP
CY2020	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q4	verv	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering
CY2020	verv	Proceed From Shareholder Loan ProceedFromShareholderLoan
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	us-gaap	Provision For Lease Losses ProvisionForLeaseLosses
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Deferred Tax Assets Regulatory Assets And Liabilities DeferredTaxAssetsRegulatoryAssetsAndLiabilities
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001840574
CY2020	verv	Issuance Of Preferred Stock Tranche Liability IssuanceOfPreferredStockTrancheLiability
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	verv	Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40489
CY2021	dei	Entity Registrant Name EntityRegistrantName	VERVE THERAPEUTICS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-4800132
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Technology Square, Suite 901
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2021	dei	City Area Code CityAreaCode	617
CY2021	dei	Local Phone Number LocalPhoneNumber	603-0070
CY2021	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	VERV
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	463000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1839000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5237000
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	2185000000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48576595
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64330000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8993000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	296112000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	63119000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6686000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1854000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	367128000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	73966000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7224000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3984000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2696000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0
CY2021Q4	us-gaap	Assets Assets	384124000
CY2020Q4	us-gaap	Assets Assets	78413000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7077000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	36000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12992000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7189000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1955000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2021Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0
CY2020Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	90000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22024000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7315000
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	125000
CY2021Q4	verv	Success Payment Liability SuccessPaymentLiability	4371000
CY2020Q4	verv	Success Payment Liability SuccessPaymentLiability	2806000
CY2021Q4	verv	Antidilution Rights Liability AntidilutionRightsLiability	0
CY2020Q4	verv	Antidilution Rights Liability AntidilutionRightsLiability	6916000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	377000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2021Q4	us-gaap	Liabilities Liabilities	26772000
CY2020Q4	us-gaap	Liabilities Liabilities	17162000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	255000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48511735
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3123424
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48511735
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2585789
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	49000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	544381000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2616000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-228000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186850000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66536000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	357352000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-63909000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	384124000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78413000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68202000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35371000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11144000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18865000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5256000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2498000
CY2021	us-gaap	Operating Expenses OperatingExpenses	87067000
CY2020	us-gaap	Operating Expenses OperatingExpenses	40627000
CY2019	us-gaap	Operating Expenses OperatingExpenses	13642000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-87067000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-40627000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-13642000
CY2021	verv	Change In Fair Value Of Preferred Stock Tranche Liabilities ChangeInFairValueOfPreferredStockTrancheLiabilities	0
CY2020	verv	Change In Fair Value Of Preferred Stock Tranche Liabilities ChangeInFairValueOfPreferredStockTrancheLiabilities	2507000
CY2019	verv	Change In Fair Value Of Preferred Stock Tranche Liabilities ChangeInFairValueOfPreferredStockTrancheLiabilities	-4883000
CY2021	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	25574000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-236000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	9000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-120550000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45705000
CY2020	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	5359000
CY2019	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	982000
CY2021	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	7815000
CY2020	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	2387000
CY2019	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	68000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	142000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	162000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	278000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-33247000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5077000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5655000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-120314000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45704000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19297000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.48
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-20.31
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-15.11
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26872036
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2250093
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1277156
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-120314000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45704000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19297000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19288000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-1484000
CY2019	verv	Issuance Costs Of Series A Convertible Preferred Stock IssuanceCostsOfSeriesAConvertiblePreferredStock	10000
CY2019	verv	Issuance Of Series A Convertible Preferred Stock And Settlement Of Tranche Right Liability IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability	84000
CY2019	verv	Stock Issued During Period Value Licensor Institutions StockIssuedDuringPeriodValueLicensorInstitutions	748000
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000
CY2019	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	24000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	446000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19297000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-19553000
CY2020	verv	Issuance Of Series A Convertible Preferred Stock And Settlement Of Tranche Right Liability IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability	7000000.0
CY2020	verv	Issuance Costs Of Series A Convertible Preferred Stock IssuanceCostsOfSeriesAConvertiblePreferredStock	22000
CY2020	verv	Issuance Costs Of Series A2 Convertible Preferred Stock IssuanceCostsOfSeriesA2ConvertiblePreferredStock	112000
CY2020	verv	Stock Issued During Period Additional Shares Value Licensor Institutions StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions	487000
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	850000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45704000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-63909000
CY2021	verv	Issuance Costs Of Series B Convertible Preferred Stock IssuanceCostsOfSeriesBConvertiblePreferredStock	241000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	218919000
CY2021	verv	Issuance Costs Of Common Stock From Initial Public Offering IssuanceCostsOfCommonStockFromInitialPublicOffering	25098000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	281584000
CY2021	verv	Stock Issued During Period Value Licensor Institutions StockIssuedDuringPeriodValueLicensorInstitutions	32490000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	966000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	780000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-236000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7072000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-120314000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	357352000
CY2021	us-gaap	Profit Loss ProfitLoss	-120314000
CY2020	us-gaap	Profit Loss ProfitLoss	-45704000
CY2019	us-gaap	Profit Loss ProfitLoss	-19297000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1535000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1328000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	106000
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0
CY2020	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0
CY2019	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2781000
CY2021	us-gaap	Provision For Lease Losses ProvisionForLeaseLosses	1842000
CY2019	us-gaap	Provision For Lease Losses ProvisionForLeaseLosses	0
CY2021	verv	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	1508000
CY2020	verv	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	380000
CY2019	verv	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	-72000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	7072000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	850000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	446000
CY2021	verv	Change In Fair Value Of Preferred Stock Tranche Liabilities ChangeInFairValueOfPreferredStockTrancheLiabilities	0
CY2020	verv	Change In Fair Value Of Preferred Stock Tranche Liabilities ChangeInFairValueOfPreferredStockTrancheLiabilities	2507000
CY2019	verv	Change In Fair Value Of Preferred Stock Tranche Liabilities ChangeInFairValueOfPreferredStockTrancheLiabilities	-4883000
CY2021	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	25574000
CY2020	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	5359000
CY2019	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	982000
CY2021	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	7815000
CY2020	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	2387000
CY2019	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	68000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7528000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1582000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	182000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6829000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1898000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1735000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5977000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6071000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	945000
CY2021	verv	Success Of Payment Liability SuccessOfPaymentLiability	-6250000
CY2020	verv	Success Of Payment Liability SuccessOfPaymentLiability	0
CY2019	verv	Success Of Payment Liability SuccessOfPaymentLiability	0
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1940000
CY2019	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0
CY2021	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	0
CY2020	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	51000
CY2019	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	163000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77880000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35265000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7442000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4359000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3424000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1857000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	371494000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	98484000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22001000
CY2021	verv	Maturities Of Marketable Securities MaturitiesOfMarketableSecurities	136755000
CY2020	verv	Maturities Of Marketable Securities MaturitiesOfMarketableSecurities	50781000
CY2019	verv	Maturities Of Marketable Securities MaturitiesOfMarketableSecurities	11100000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-239098000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51127000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12758000
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	93759000
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	92616000
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	18040000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	285214000
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2021	verv	Proceed From Shareholder Loan ProceedFromShareholderLoan	0
CY2019	verv	Proceed From Shareholder Loan ProceedFromShareholderLoan	-110000
CY2021	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	3630000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	966000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11000
CY2021	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0
CY2019	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	24000
CY2021	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP	780000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	377089000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	92627000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17954000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	60111000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6235000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2246000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9456000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3221000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5467000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69567000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9456000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3221000
CY2021	verv	Property And Equipment Additions Included In Accounts Payable And Accrued Expenses PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses	503000
CY2020	verv	Property And Equipment Additions Included In Accounts Payable And Accrued Expenses PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses	86000
CY2019	verv	Property And Equipment Additions Included In Accounts Payable And Accrued Expenses PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses	556000
CY2021	verv	Settlement Of Tranche Right Lliability SettlementOfTrancheRightLliability	0
CY2019	verv	Issuance Of Preferred Stock Tranche Liability IssuanceOfPreferredStockTrancheLiability	84000
CY2021	verv	Settlement Of Tranche Right Lliability SettlementOfTrancheRightLliability	0
CY2020	verv	Settlement Of Tranche Right Lliability SettlementOfTrancheRightLliability	7064000
CY2021	verv	Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering	218919000
CY2021	verv	Settlement Of Antidilution Rights Liability By Issuing Common Stock SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock	32490000
CY2020	verv	Settlement Of Antidilution Rights Liability By Issuing Common Stock SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock	487000
CY2019	verv	Settlement Of Antidilution Rights Liability By Issuing Common Stock SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock	135000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	809000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Nature of the business and basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Organization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Verve Therapeutics, Inc. (the “Company” or “Verve”) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company’s principal offices are located in Cambridge, Massachusetts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Liquidity and capital resources</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On June 21, 2021, the Company completed its initial public offering, or IPO, in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,141,157</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,105,368</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">306.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The Company received approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">281.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in net proceeds after deducting underwriting discounts and offering expenses payable by the Company. In connection with the IPO, all outstanding shares of convertible preferred stock converted into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27,720,923</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company’s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In connection with the Company's IPO, the Company effected a </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one-for-9.2595</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> reverse stock split of the Company’s issued and outstanding common stock. Accordingly, all shares of common stock and per share amounts, as well as the conversion ratio of the Company’s outstanding convertible preferred stock, for all periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split, including reclassification of par and additional paid-in capital amounts as a result of the reverse stock split.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Basis of presentation and liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred losses since its inception, including losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">186.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. To date, the Company has funded its operations primarily through equity offerings. Through December 31, 2021, the Company had raised an aggregate $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">523.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in gross proceeds from the sales of its preferred stock in private placements and common stock in its IPO. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company expects that its cash, cash equivalents and marketable securities as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> will </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">be sufficient to fund its operations for at least the next twelve months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">strategy. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-120300000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45700000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19300000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186900000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the IPO), convertible preferred stock, preferred stock tranche liability, stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.</span>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64330000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8993000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	5237000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	463000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69567000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9456000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Concentrations of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</span>
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021Q4	verv	Percentage Of Tax Benefit Realized PercentageOfTaxBenefitRealized	0.50
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	296340000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	228000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	296112000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	63111000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	63119000
CY2021	verv	Remaining Contractual Maturities Of Marketable Securities Term RemainingContractualMaturitiesOfMarketableSecuritiesTerm	P1Y
CY2020	verv	Remaining Contractual Maturities Of Marketable Securities Term RemainingContractualMaturitiesOfMarketableSecuritiesTerm	P1Y
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9557000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4782000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2333000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	798000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7224000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3984000
CY2021	us-gaap	Depreciation Depreciation	1500000
CY2020	us-gaap	Depreciation Depreciation	1300000
CY2019	us-gaap	Depreciation Depreciation	100000
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	354239000
CY2021Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	4371000
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	69843000
CY2020Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	9722000
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	58100000
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6700000
CY2019Q4	verv	Research And Development Expense Of Antidilution Rights Liability ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability	1200000
CY2020	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	5400000
CY2019	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	1000000.0
CY2021Q4	verv	Fair Value Of Common Stock Per Share FairValueOfCommonStockPerShare	36.87
CY2020Q4	verv	Fair Value Of Common Stock Per Share FairValueOfCommonStockPerShare	8.24
CY2019Q4	verv	Fair Value Of Common Stock Per Share FairValueOfCommonStockPerShare	2.59
CY2020	verv	Cumulative Probability Of Triggering Event CumulativeProbabilityOfTriggeringEvent	0.70
CY2019	verv	Cumulative Probability Of Triggering Event CumulativeProbabilityOfTriggeringEvent	0.11
CY2019	verv	Fair Value Assumptions Expected Term1 FairValueAssumptionsExpectedTerm1	P2Y10M20D
CY2019Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	12034000
CY2020	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	7064000
CY2020	verv	Common Stock Issued During Period Value New Issues CommonStockIssuedDuringPeriodValueNewIssues	-487000
CY2020	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	5239000
CY2020Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	9722000
CY2021	verv	Common Stock Issued During Period Value New Issues CommonStockIssuedDuringPeriodValueNewIssues	-32490000
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	6250000
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	33389000
CY2021Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	4371000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	6050000
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1636000
CY2021Q4	verv	Accrued External Research And Development Expenses AccruedExternalResearchAndDevelopmentExpenses	5041000
CY2020Q4	verv	Accrued External Research And Development Expenses AccruedExternalResearchAndDevelopmentExpenses	4827000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1109000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	303000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	792000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	423000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12992000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7189000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1923000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	747000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2278000
CY2021	us-gaap	Lease Cost LeaseCost	4948000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2021000
CY2021Q4	verv	Lessee Operating Lease Incremental Borrowing Rate LesseeOperatingLeaseIncrementalBorrowingRate	0.0157
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y10M24D
CY2021Q4	verv	Lease Commencement Date LeaseCommencementDate	2021-12
CY2021Q4	verv	Lease Noncancelable Term LeaseNoncancelableTerm	P12M
CY2021Q4	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	The Company has the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term, which the Company is not reasonably certain of exercising.
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12951000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9958000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10257000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10565000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10882000
CY2021Q4	verv	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	54158000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	108771000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	108758000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.761
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.009
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.004
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3888823
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.15
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	47691000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4745788
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.56
CY2021	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	Each share of Series A Preferred, Series A-2 Preferred and Series B Preferred may be converted at any time, at the option of the holder, into shares of common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The initial conversion price for each of the Series A Preferred, Series A-2 Preferred and Series B Preferred (each as may be adjusted for certain dilutive events) was $0.598, $0.8041 and $1.2182 per share, respectively. Each series of Series A Preferred, Series A-2 Preferred and Series B Preferred automatically converted into shares of common stock on a 1:1 conversion ratio (as may be adjusted for certain dilutive events) at the earlier of the closing of an initial public offering of the Company’s common stock with gross proceeds to the Company of at least $50.0 million and a purchase price of $22.34 per share, or at the election of the holders of at least two-thirds of the then-outstanding shares of Preferred Stock.
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	22.34
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4632042
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7072000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	850000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	446000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.777
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.848
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.13
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2869946
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.66
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	599838
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.61
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	39636
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.56
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6119295
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.44
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	171636000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1373507
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y10M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	123945000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-120314000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45704000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19297000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26872036
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2250093
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1277156
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.48
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-20.31
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-15.11
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6151295
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23814000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8562142
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	120300000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	45700000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	19300000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.313
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.296
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.179
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.009
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.001
CY2021	verv	Effective Income Tax Rate Reconciliation Executive Compensation Percent EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent	-0.011
CY2020	verv	Effective Income Tax Rate Reconciliation Executive Compensation Percent EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent	0.000
CY2019	verv	Effective Income Tax Rate Reconciliation Executive Compensation Percent EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent	0.000
CY2021	verv	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.001
CY2020	verv	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	0.011
CY2019	verv	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.058
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.061
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.068
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.017
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.045
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.011
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33409000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12973000
CY2021Q4	verv	Deferred Tax Assets Capitalized Costs Net Of Amortization DeferredTaxAssetsCapitalizedCostsNetOfAmortization	12395000
CY2020Q4	verv	Deferred Tax Assets Capitalized Costs Net Of Amortization DeferredTaxAssetsCapitalizedCostsNetOfAmortization	855000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6098000
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	682000
CY2020Q4	verv	Deferred Tax Assets Antidilultion Liability DeferredTaxAssetsAntidilultionLiability	2815000
CY2021Q4	verv	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	1117000
CY2020Q4	verv	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	149000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	76000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	61000
CY2021Q4	us-gaap	Deferred Tax Assets Regulatory Assets And Liabilities DeferredTaxAssetsRegulatoryAssetsAndLiabilities	533000
CY2021Q4	verv	Deferred Tax Asset Accrued Expenses DeferredTaxAssetAccruedExpenses	2852000
CY2020Q4	verv	Deferred Tax Asset Accrued Expenses DeferredTaxAssetAccruedExpenses	905000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56480000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18440000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	899000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1061000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	55080000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	17379000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	55080000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17379000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1061000
CY2021Q4	verv	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	-501000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1400000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	37700000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13600000
CY2021	verv	Change In Ownership Description ChangeInOwnershipDescription	An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	300000
CY2020	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	400000
CY2019	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	400000
CY2021	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	537633
CY2020	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	537635
CY2019	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	537635
CY2021	verv	Option And License Issue Fees OptionAndLicenseIssueFees	200000
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	6500

Files In Submission

Name	View Source	Status
0000950170-22-003499-index-headers.html	Edgar Link	pending
0000950170-22-003499-index.html	Edgar Link	pending
0000950170-22-003499.txt	Edgar Link	pending
0000950170-22-003499-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img242628118_0.jpg	Edgar Link	pending
img242628118_1.jpg	Edgar Link	pending
img242628118_10.jpg	Edgar Link	pending
img242628118_11.jpg	Edgar Link	pending
img242628118_12.jpg	Edgar Link	pending
img242628118_13.jpg	Edgar Link	pending
img242628118_14.jpg	Edgar Link	pending
img242628118_15.jpg	Edgar Link	pending
img242628118_16.jpg	Edgar Link	pending
img242628118_17.jpg	Edgar Link	pending
img242628118_18.jpg	Edgar Link	pending
img242628118_19.jpg	Edgar Link	pending
img242628118_2.jpg	Edgar Link	pending
img242628118_20.jpg	Edgar Link	pending
img242628118_21.jpg	Edgar Link	pending
img242628118_22.jpg	Edgar Link	pending
img242628118_23.jpg	Edgar Link	pending
img242628118_24.jpg	Edgar Link	pending
img242628118_25.jpg	Edgar Link	pending
img242628118_26.jpg	Edgar Link	pending
img242628118_27.jpg	Edgar Link	pending
img242628118_28.jpg	Edgar Link	pending
img242628118_29.jpg	Edgar Link	pending
img242628118_3.jpg	Edgar Link	pending
img242628118_4.jpg	Edgar Link	pending
img242628118_5.jpg	Edgar Link	pending
img242628118_6.jpg	Edgar Link	pending
img242628118_7.jpg	Edgar Link	pending
img242628118_8.jpg	Edgar Link	pending
img242628118_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
verv-20211231.htm	Edgar Link	pending
verv-20211231.xsd	Edgar Link	pending
verv-20211231_cal.xml	Edgar Link	unprocessable
verv-20211231_def.xml	Edgar Link	unprocessable
verv-20211231_htm.xml	Edgar Link	completed
verv-20211231_lab.xml	Edgar Link	unprocessable
verv-20211231_pre.xml	Edgar Link	unprocessable
verv-ex10_14.htm	Edgar Link	pending
verv-ex10_19.htm	Edgar Link	pending
verv-ex10_4.htm	Edgar Link	pending
verv-ex10_5.htm	Edgar Link	pending
verv-ex10_7.htm	Edgar Link	pending
verv-ex23_1.htm	Edgar Link	pending
verv-ex31_1.htm	Edgar Link	pending
verv-ex31_2.htm	Edgar Link	pending
verv-ex32_1.htm	Edgar Link	pending
verv-ex32_2.htm	Edgar Link	pending
verv-ex4_3.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VERV
Verve Therapeutics, Inc. Stock $verv

2022 Q1 Form 10-K Financial Statement

#000095017022003499 Filed on March 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VERV Verve Therapeutics, Inc. Stock $verv

2022 Q1 Form 10-K Financial Statement

#000095017022003499 Filed on March 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VERV
Verve Therapeutics, Inc. Stock $verv